| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8757115 | Chinese Medical Sciences Journal | 2018 | 11 Pages |
Abstract
RTX treatment in IMN was efficient, well tolerated and safe. More than 60% patients can reach partial remission or CR in 24 months, and relapse is rare. Adverse events of RTX are mostly infusion-related reactions and generally mild.
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Peimei Zou, Hang Li, Jianfang Cai, Zhenjie Chen, Chao Li, Xuewang Li,